Introduction

As artificial intelligence matures, its role in cancer care is expanding from detection into treatment selection and patient monitoring. The AI in oncology market reflects that shift. Polaris Market Research reports that the market was valued at USD 6.51 billion in 2025 and is expected to grow at a CAGR of 27.1% from 2026 to 2034, reaching USD 56.44 billion by 2034. The report segments the market by component, cancer type, treatment type and region.

This article examines the treatment and cancer-type segments, the clinical use cases behind them and the regional picture.

Treatment Segments: Chemotherapy and Immunotherapy

Chemotherapy held the largest treatment share in 2025, at 36.7%. The segment benefits from the rising use of AI to personalize chemotherapy regimens, optimize drug selection and minimize dosage-related side effects. The report notes that AI helps healthcare professionals build personalized digital profiles for patients, enabling dosage to be customized during treatment, and that the use of AI to deliver personalized chemotherapy with reduced dosage and fewer side effects is fostering adoption. As context, the American Cancer Society reports that an estimated 60% of Stage 4 bladder cancer patients undergo chemotherapy.

Immunotherapy is expected to grow at a substantial pace, driven by positive outcomes in clinical studies and an increasing number of approvals. In January 2023, a new AI-based biomarker was introduced to help predict immunotherapy response in lung cancer patients. According to a ScienceDirect article cited in the report, AI can identify major histocompatibility complex patterns associated with a 91.66% accuracy rate in predicting immunotherapy response.

The report adds that the incorporation of AI enhances the accuracy of immunotherapy.

Cancer-Type Segments: Breast Cancer and Brain Tumors

Breast cancer accounted for the largest cancer-type share in 2025, at 31.9%. The increasing global prevalence of breast cancer and growing adoption of AI-assisted screening and diagnosis support the segment. The report cites the American Society of Clinical Oncology, which reported approximately 2,261,419 new cancer cases worldwide in 2020 and projected an estimated 297,790 new breast cancer cases in the U.S. in 2023.

The brain tumor segment is expected to grow rapidly. Integrating AI with advanced imaging supports accurate brain tumor diagnosis during surgery within a short window of 3 minutes, helping distinguish tumors from healthy tissue. Deep learning models have also proven beneficial for neurologists. Lung, prostate and colorectal cancers are also covered among the report’s segments.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/ai-in-oncology-market 

Predictive Capabilities and Early Intervention

Traditional oncology has limited ability to forecast disease progression and treatment response. AI-powered oncology uses predictive analytics to estimate cancer risks, outcomes and therapy effectiveness. It also supports earlier intervention, optimized treatments, and improved patient monitoring and survival outcomes.

The report identifies precision medicine and early cancer detection capabilities as key growth drivers, reinforced by growing prevalence of cancer, advances in diagnostics technology and rising demand for early and precise diagnosis. Research investment is also moving upstream. In June 2026, the National Cancer Center launched a research initiative focused on AI technology that can predict the likelihood of success for drug candidates before they enter the expensive and time-consuming drug development process.

Looking further out, surging investment in AI-driven cancer research and targeted therapies is expected to position AI as a transformative force in the future of global oncology care.

Report Coverage and Segmentation

The report segments the market by component into software solutions, hardware and services. By cancer type, it covers breast, lung, prostate and colorectal cancer, brain tumor and others. By treatment type, it covers chemotherapy, radiotherapy, immunotherapy and others.

Regionally, the scope spans North America (U.S., Canada), Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia), Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea), Latin America (Brazil, Mexico, Argentina), and the Middle East and Africa (Saudi Arabia, UAE, Israel, South Africa).

Regional Insights

North America held the largest regional share in 2025, at 42.8%. The report attributes this to well-established digital infrastructure, favorable reimbursement policies and government initiatives promoting AI adoption in healthcare, alongside the growing prevalence of various cancers.

Asia Pacific is projected to register the highest CAGR, at 32.4%. Growth stems from increasing digitalization in diagnostic laboratories and hospitals, a growing geriatric population and rising cancer prevalence. According to Globocan data cited in the report, there were approximately 19 million new cancer cases globally in 2020, with Asia Pacific contributing 9.7 million. The report’s regional scope also covers Europe, Latin America, and the Middle East and Africa.

Competitive Landscape and Key Players

Companies operating in the global market include Azra AI, IBM, Siemens Healthcare GmbH, Intel Corporation, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., ConcertAI, Median Technologies and PathAI.

The report’s company profiles cover each player’s overview, financial performance, product benchmarking and recent developments. It rates rivalry among existing firms as high and the threat of new entrants as low.

Conclusion

The AI in oncology market is moving beyond detection toward personalized treatment and risk prediction. Chemotherapy and immunotherapy use cases, a strong breast cancer segment and fast-growing brain tumor applications show where clinical value is emerging, while North America’s lead and Asia Pacific’s growth outlook give vendors clear regional priorities.

More Trending Latest Reports By Polaris Market Research:

Autonomous Port Operations Systems Market

Insecticides Market

Remote Monitoring and Control Market

Biodiversity Credit Market

U.S. Rockets and Missiles Market

Psoriasis Drug Market

Fuel Cell Market

Automotive Wiring Harness Market

Dc Distribution Network Market